- Home
- KOD
as 12-20-2024 3:38pm EST
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 186.3M | IPO Year: | 2018 |
| Target Price: | $6.80 | AVG Volume (30 days): | 484.9K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.19 - $11.60 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Kodiak Sciences Inc News
KOD Breaking Stock News: Dive into KOD Ticker-Specific Updates for Smart Investing
Zacks
12 days ago
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential
MT Newswires
13 days ago
Top Midday Gainers
Benzinga
13 days ago
Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock
MT Newswires
13 days ago
Kodiak Sciences Shares Soar After Upgrade From Jefferies
MT Newswires
13 days ago
Jefferies Upgrades Kodiak Sciences to Buy From Hold, Raises Price Target to $20 From $6
Zacks
a month ago
Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?
Zacks
a month ago
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
PR Newswire
a month ago
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Compare KOD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KOD Kodiak Sciences Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.